Adverse events associated with nevirapine use in pregnancy: a systematic review and meta-analysis
AffiliationMédecins Sans Frontières, Geneva, Switzerland. firstname.lastname@example.org
MetadataShow full item record
AbstractThe risk of adverse drug events associated with nevirapine (NVP) is suggested to be greater in pregnant women. We conducted a systematic review and meta-analysis of severe adverse events in HIV-positive women who initiated NVP while pregnant.
PublisherLippincott Williams & Wilkins
- Adverse events in a cohort of HIV infected pregnant and non-pregnant women treated with nevirapine versus non-nevirapine antiretroviral medication.
- Authors: Aaron E, Kempf MC, Criniti S, Tedaldi E, Gracely E, Warriner A, Kumar R, Bachmann LH
- Issue date: 2010 Sep 7
- Safety of nevirapine in HIV-infected pregnant women initiating antiretroviral therapy at higher CD4 counts: a systematic review and meta-analysis.
- Authors: Bera E, Mia R
- Issue date: 2012 Oct 8
- Lack of increased hepatotoxicity in HIV-infected pregnant women receiving nevirapine compared with other antiretrovirals.
- Authors: Ouyang DW, Brogly SB, Lu M, Shapiro DE, Hershow RC, French AL, Leighty RM, Thompson B, Tuomala RE
- Issue date: 2010 Jan 2
- Antiretroviral therapy (ART) for treating HIV infection in ART-eligible pregnant women.
- Authors: Sturt AS, Dokubo EK, Sint TT
- Issue date: 2010 Mar 17
- Nevirapine-associated hepatotoxicity and rash among HIV-infected pregnant women in Kenya.
- Authors: Peters PJ, Polle N, Zeh C, Masaba R, Borkowf CB, Oyaro B, Omolo P, Ogindo P, Ndivo R, Angira F, Lando R, Fowler MG, Weidle PJ, Thomas TK
- Issue date: 2012 Mar-Apr